Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932276 | 0.84 | MMP2 (0.45) | MMP2MMP9 | |
| SCHEMBL11380958 | 0.82 | CES2 (0.43) | MMP2MMP9MMP12GPR84FFAR1 | |
| SCHEMBL10420390 | 0.78 | PPARA (0.48) | PPARAPPARG | |
| SCHEMBL10419487 | 0.77 | LMNA (0.42) | PPARAPPARG | |
| SCHEMBL10419483 | 0.75 | PPARA (0.45) | PPARAPPARG | |
| SCHEMBL10419211 | 0.74 | PPARA (0.47) | MMP2PPARAPPARGMMP3 | |
| SCHEMBL10419958 | 0.72 | CNR1 (0.41) | PPARAPPARGMMP12 | |
| Hydroxyamine SCHEMBL7066257 | 0.71 | CNR2 (0.38) | PPARGPTGESALOX5 | |
| SCHEMBL6928744 | 0.70 | PTPN1 (0.39) | MMP2MMP9PTPN1 | |
| SCHEMBL11364294 | 0.69 | HDAC1 (0.39) | GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6462073-B2 | METALLOPROTEASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP2 3/4885MMP9 16/4885PPARA 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.